Voluntary announcement - on-market share repurchase
Filed with HKEX · Stock code 7630 · · 2 pages · English
Summary by 6ix AI
IMPACT Therapeutics, Inc. has announced a voluntary share repurchase program for its H shares on the Hong Kong Stock Exchange. The board plans to repurchase shares for a total amount up to a specified limit, using its own financial resources. The repurchase is intended to enhance shareholder value and demonstrate confidence in the company's business outlook. As of now, no shares have been repurchased under this mandate, and future repurchases will depend on market conditions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
IMPACT Therapeutics, Inc. on 6ix
Earlier from IMPACT Therapeutics
- Voluntary announcement - poster presentation of latest clinical data for senaparib and PARP1-selective inhibitors IMP1734 and IMP1707 at 2026 ESMO congress
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - positive CHMP opinion for senaparib, as potential first-line maintenance treatment of advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer
- 2026 Interim Report
- IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
Follow IMPACT Therapeutics into a list and get an email when it puts out news.
Follow IMPACT Therapeutics